tbuckley/cabot-search huggingface dataset:
RAB43 facilitates cross-presentation of cell-associated antigens by CD8α+ dendritic cells
Authors: Nicole M. Kretzer, Derek J. Theisen, Roxane Tussiwand, Carlos G. Briseño, Gary E. Grajales-Reyes, Xiaodi Wu, Vivek Durai, Jörn Albring, Prachi Bagadia, Theresa L. Murphy, Kenneth M. Murphy
Journal: The Journal of Experimental Medicine (2016)

In this study, to examine cross-presentation by classical dendritic cells (DCs; cDCs), we evaluated the role of RAB43, a protein found to be selectively expressed by Batf3-dependent CD8α+ and CD103+ compared with other DC subsets and immune lineages. Using a specific monoclonal antibody, we localized RAB43 expression to the Golgi apparatus and LAMP1− cytoplasmic vesicles. Mice with germline or conditional deletion of Rab43 are viable and fertile and have normal development of cDCs but show a defect for in vivo and in vitro cross-presentation of cell-associated antigen. This defect is specific to cDCs, as Rab43-deficient monocyte-derived DCs showed no defect in cross-presentation of cell-associated antigen. These results suggest that RAB43 provides a specialized activity used in cross-presentation selectively by CD8α+ DCs but not other antigen-presenting cells.
Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031.
Authors: Kirk R. Schultz, W. Paul Bowman, William Slayton, Alex Aledo, Meenakshi Devidas, Harland Sather, Michael J. Borowitz, Stella M. Davies, Michael Trigg, Bernice Pasut, Dean Jorstad, Tammie Eslinger, Laura E. Burden, Chenguang Wang, Robert Rutledge, Paul S. Gaynon, Andrew J. Carroll, Nyla A. Heerema, Naomi Winick, Stephen Hunger, William L. Carroll, Bruce Camitta
Journal: Blood (2007)
RIAM, a New Rap1 Effector, Functions Downstream of Rap1 and Regulates Rap1 Localization at the Plasma Membrane and Rap1-Induced Adhesion.
Authors: Esther M. Lafuente, Christopher V. Carman, Matthias Krause, Timothy A. Springer, Frank B. Gertler, Vassiliki A. Boussiotis
Journal: Blood (2004)
The Longitudinal Relationship Between Inflammatory Markers and Patient-Reported Symptom Severity During Induction Therapy for Multiple Myeloma
Authors: Xin Shelley Wang, Ping Liu, Charles S Cleeland, James M Reuben, Evan N Cohen, Lori Williams, Gary M Mobley, Jacqueline Joy, Venus M Ilagan, Katherine R Gilmore, Tito R Mendoza, Valen E Johnson
Journal: Blood (2011)
Marked Upregulations of Survivin and Aurora-B Kinase Are Associated with Disease Progression in the Myelodysplastic Syndromes,
Authors: Akira Yoshida, Kouichi Zokumasu, Takahiro Yamauchi, Kazutaka Takagi, Shinji Kishi, Yoshimasa Urasaki, Kaoru Tohyama, Takanori Ueda
Journal: Blood (2011)
Modulation of Cancer Cell-Associated Procoagulant Activity (PCA) by a Novel, Small Molecule, Orally Active Inhibitor of Oxidative Stress Pathways
Authors: Shaymaa S. Mousa, Ghanshyam Patil, Lawrence Lansing, Emmy Dier, Theresa Kannanayakal, Frederick Rickles, Shaker S Mousa
Journal: Blood (2008)
Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.
Authors: Giuliana Alimena, Massimo Breccia, Luigia Luciano, Fabrizio Quarantelli, Daniela Diverio, Barbara Izzo, Biagio De Angelis, Marco Mancini, Roberto Latagliata, Ida Carmosino, Mauro Nanni, Bruno Rotoli, Franco Mandelli, Fabrizio Pane
Journal: Blood (2006)
MicroRNAs 155, -221 and -222 Control Megakaryopoiesis at Progenitor and Precursor Level through Ets-1 Multitargeting.
Authors: Giovanna Marziali, Valentina Lulli, Simona Coppola, Paolo Romania, Laura Fontana, Francesca Liuzzi, Mauro Biffoni, Nadia Felli, Carlo Maria Croce, Elvira Pelosi, Cesare Peschle
Journal: Blood (2006)
Preventing HIV among Women — A Step Forward, but Much Farther to Go
Authors: Adaora A. Adimora
Journal: New England Journal of Medicine (2016)

The 900,000 new HIV infections among women globally in 2015 attest to the urgent need for the dissemination of effective new HIV-prevention products for women. Most women are infected with HIV by means of sexual activity with men. Therefore, the treatment of persons with HIV is one of the most effective strategies for the prevention of new cases of HIV infection among women. However, few countries have attained the level of antiretroviral coverage in the population that is required to eliminate transmission, and women need prevention methods that they can control themselves. Long-acting products that decrease the burden of adherence . . .
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma
Authors: S Mithraprabhu, T Khong, M Ramachandran, A Chow, D Klarica, L Mai, S Walsh, D Broemeling, A Marziali, M Wiggin, J Hocking, A Kalff, B Durie, A Spencer
Journal: Leukemia (2016)
A Post-Marketing Surveillance Study of the Safety and Efficiacy of Refacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) (St. Louis-Derived Active Substance in the Treatment and Prevension of Bleeding Episodes in Hemophilia a Patients.
Authors: Jay M. Feingold, Mark P. Smith, Richard Littlewood, Paul Giangrande
Journal: Blood (2004)
HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival
Authors: Marc Poch Martell, Nada Hamad, Fotios V. Michelis, Jieun Uhm, Feras Alfraih, Mohamed Shanavas, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel, Dennis Kim
Journal: Blood (2014)
Prognostic Implications of CD14 Positivity in Acute Myeloid Leukemia Arising From Myleodysplastic Syndrome,
Authors: Yunsuk Choi, Sungdoo Kim, Young-Hun Park, Jae Seok Lee, Dae-Young Kim, Jung-Hee Lee, Kyoo-Hyung Lee, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ah Rang Jung, Je-Hwan Lee
Journal: Blood (2011)
Association of Neurodevelopmental Abnormalities Is a Common Clinical Character in Japanese Patients with Severe Congenital Neutropenia Due to HAX1 Deficiency.
Authors: Satoshi Okada, Nobutsune Ishikawa, Kenichiro Shirao, Miyuki Tsumura, Takashi Satoh, Yoshinori Ohno, Shin’ichiro Yasunaga, Motoaki Ohtsubo, Yoshihiro Takihara, Masao Kobayashi
Journal: Blood (2007)
A Signal Hierarchy Model of Alloreactive T Cell Trafficking for the Organ Manifestation in Acute Graft-Versus-Host Disease.
Authors: Andreas Beilhack, Stephan Schulz, Jeanette Baker, Georg F. Beilhack, Ryosei Nishimura, Gilad Landan, Enosh M. Baker, Edward I. Herman, Christopher H. Contag, Robert S. Negrin
Journal: Blood (2006)
Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients,
Authors: Bruno Paiva, Maria Victoria Mateos, Lucía López-Corral, María-Belén Vidriales, Miguel T. Hernandez, Joan Bargay, Felipe de Arriba, Javier De La Rubia, Ana-Isabel Teruel, Pilar Giraldo, Laura Rosiñol, Felipe Prosper, Albert Oriol, Jose Hernández, Graça Esteves, Fernando Leal da Costa, Juan José Lahuerta, Joan Blade, Jesus F. San Miguel
Journal: Blood (2011)
Efficacy and Safety of Rituximab in Adult Patients with Idiopathic Relapsed or Refractory Thrombotic Thrombocytopenic Purpura (TTP). Results of a Spanish Multicenter Study.
Authors: Javi er de la Rubia, Federico Moscardo, María J Gómez, Ramon Guardia, Pilar Rodriguez, Ana Sebrango, Concha Zamora, Guillermo Deben, Rosa Goterri, Rafaela Lopez, Francisco Peña, Micola Pujol
Journal: Blood (2008)
Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902
Authors: Selina Luger, Victoria X Wang, Elisabeth Paietta, Rhett P. Ketterling, Witold Rybka, Hillard M. Lazarus, Mark R Litzow, Jacob M. Rowe, Richard A. Larson, Frederick R Appelbaum, Martin S. Tallman
Journal: Blood (2015)
T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation with Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients with Relapsed Multiple Myeloma and High-Risk Cytogenetics
Authors: Guenther Koehne, Heather Landau, Hani Hassoun, Alex Lesokhin, Nikoletta Lendvai, Michael A. Rosenzweig, Glenn Heller, Sergio Giralt
Journal: Blood (2011)
Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar®) Correlates with Response to Therapy
Authors: Andrzej J. Jakubowiak, Malathi Hari, Tara Kendall, Yasser Khaled, Shin Mineishi, Ammar Al-Zoubi, Mark S. Kaminski, Ivan Maillard
Journal: Blood (2008)
Committed Ventricular Progenitors in the Islet-1 Lineage Expand and Assemble Into Functional Ventricular Heart Muscle
Authors: Peter Van der Meer, Ibrahim J. Domian, Murali Chiravuri, Adam F. Feinberg, Sean M. Wu, Kevin K. Parker, Kenneth R. Chien
Journal: Journal of the American College of Cardiology (2009)
Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.
Authors: Sonali M. Smith, David L. Grinblatt, Thomas Gajewski, Helena Harlin, Karen Welborne, Kathy Conner, Richard A. Larson, Elizabeth Rich, Olatoyosi Odenike, Todd Zimmerman, Koen van Besien
Journal: Blood (2004)
Effect of Counting Genetic Variants on Precision Treatment for Pediatric Atopic Dermatitis
Authors: Mary Elizabeth Mathyer, Carrie C. Coughlin, Cristina de Guzman Strong
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Graft-versus-host disease targets ovary and causes female infertility in mice
Authors: Sonoko Shimoji, Daigo Hashimoto, Hidetsugu Tsujigiwa, Kohta Miyawaki, Koji Kato, Shuichiro Takahashi, Reiki Ogasawara, Takashi Jiromaru, Hiromi Iwasaki, Toshihiro Miyamoto, Koichi Akashi, Takanori Teshima
Journal: Blood (2016)
O-022 A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)
Authors: V. Morris, K. Ciombor, M. Salem, H. Nimeiri, S. Iqbal, P. Singh, B. Polite, D. Deming, E. Chan, J. Wade, T. Bekaii-Saab, R. Wolff, C. Eng
Journal: Annals of Oncology (2016)
Patient Characteristics in CD 20+ and CD 20− Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis.
Authors: Sara P. Gladney, Leonard T. Heffner, Amelia Langston, Jeannine Holden, Carol Phillips, Elliott Winton, Christopher R. Flowers, Mary Jo Lechowicz, Sagar Lonial, Edmund Waller, Hanna J. Khoury
Journal: Blood (2005)
First Line Therapy with Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Patients with Acute Myeloblastic Leukemia in First Complete Remission.
Authors: Didier Blaise, J.M. Boiron, C. Faucher, M. Mohty, J.O. Bay, K. Bilger, G. Marit, V.J. Bardoux, V. Perreau, D. Coso, A.M. Stoppa, J.A. Gastaut, J. Reiffers, D. Maraninchi, N. Vey
Journal: Blood (2004)
Abstract 2708: New approaches to overcome tyrosine kinase inhibitor resistances in chronic myeloid leukemia
Authors: Sebastian Halbach, Franziska U. Wöhrle, Sandra Braun, Tilman Brummer
Journal: Cancer Research (2015)

Abstract Chronic myeloid leukemia (CML) is driven by the hyperactive fusion kinase Bcr-Abl, generated by a chromosomal translocation between chromosome 9 and 22. This oncogenic tyrosine kinase builds up its own signaling network with various proteins such as the docking protein Gab2 or the Src kinase Lyn. As a result, the cells become addicted to the constant signals derived from this fusion kinase. This is the reason why selective Bcr Abl tyrosine kinase inhibitors (TKIs), such as Imatinib mesylate or dasatinib, became so successful in the therapy of CML. Despite the great success of these TKIs in CML treatment, TKI resistance remains a serious clinical problem. These resistances can be caused by mutations in the Bcr-Abl oncogene, like the clinical relevant T315I mutation or by aberrant activity of components of the Bcr-Abl signaling network. In that regard, we could show that the overexpression of Gab2 or the expression of a hyperactive mutant of Lyn can confer TKI resistance. Using different CML cell lines and models we aimed to identify new approaches to overcome TKI resistances caused by Bcr-Abl mutations or aberrant downstream signaling. Therefore, we screened inhibitors for their ability to overcome Gab2 mediated resistance or to inhibit the activity of T315I mutated Bcr-Abl. We identified the multikinase inhibitors sorafenib and axitinib, both clinical approved as second line drugs in renal cell or hepatocellular carcinoma, as compounds reducing the viability of Bcr-AblT315I transformed cells. Interestingly, these inhibitors were highly active against TKI resistant Bcr-Abl positive cells in contrast to non-transformed cells. These results invite for the further evaluation of sorafenib and axitinib in the treatment of TKI-resistant CML. Citation Format: Sebastian Halbach, Franziska U. Wöhrle, Sandra Braun, Tilman Brummer. New approaches to overcome tyrosine kinase inhibitor resistances in chronic myeloid leukemia. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2708. doi:10.1158/1538-7445.AM2015-2708
A Call for Frailty Screening in the Preoperative Setting
Authors: Anne M. Suskind, Emily Finlayson
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Poor Survival of CD34 Positive and CD13/33 Positive Patients in Pediatric T-Cell Acute Lymphoblastic Leukemia Is Not Explained by Expression of Multidrug Resistance Genes.
Authors: Martine van Grotel, Max M. van Noesel, M.M. Van Den Heuvel, Rob Pieters, Jules P.P. Meijerink
Journal: Blood (2007)
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS
Authors: John Koreth, Joseph Pidala, Waleska S. Perez, H. Joachim Deeg, Guillermo Garcia-Manero, Luca Malcovati, Mario Cazzola, Sophie Park, Raphael Itzykson, Lionel Ades, Pierre Fenaux, Martin Jädersten, Eva Hellstrom-Lindberg, Robert Peter Gale, C. L. Beach, Peter L. Greenberg, Martin S. Tallman, John F. DiPersio, Donald Bunjes, Daniel J. Weisdorf, Corey S. Cutler
Journal: Blood (2011)
Beneficial Effects of Myo-Inositol Oxygenase Deficiency in Cisplatin-Induced AKI
Authors: Rajesh K. Dutta, Vinay K. Kondeti, Isha Sharma, Navdeep S. Chandel, Susan E. Quaggin, Yashpal S. Kanwar
Journal: Journal of the American Society of Nephrology (2016)

Overexpression of the proximal tubular enzyme myo -inositol oxygenase (MIOX) induces oxidant stress in vitro . However, the relevance of MIOX to tubular pathobiology remains enigmatic. To investigate the role of MIOX in cisplatin-induced tubular AKI, we generated conditional MIOX-overexpressing transgenic (MIOX-TG) mice and MIOX-knockout (MIOX −/− ) mice with tubule-specific MIOX overexpression or knockout, respectively. Compared with cisplatin-treated wild-type (WT) mice, cisplatin-treated MIOX-TG mice had even greater increases in urea, creatinine, and KIM-1 levels and more tubular injury and apoptosis, but these effects were attenuated in cisplatin-treated MIOX −/− mice. Similarly, MIOX-TG mice had the highest and MIOX −/− mice had the lowest renal levels of Bax, cleaved caspase-3, and NADPH oxidase-4 expression and reactive oxygen species (ROS) generation after cisplatin treatment. In vitro , cisplatin dose-dependently increased ROS generation in LLC-PK1 cells. Furthermore, MIOX overexpression in these cells accentuated cisplatin-induced ROS generation and perturbations in the ratio of GSH to oxidized GSH, whereas MIOX-siRNA or N -acetyl cysteine treatment attenuated these effects. Additionally, the cisplatin-induced enhancement of p53 activation, NF- κ B binding to DNA, and NF- κ B nuclear translocation in WT mice was exacerbated in MIOX-TG mice but absent in MIOX −/− mice. In vitro , MIOX-siRNA or NAC treatment reduced the dose-dependent increase in p53 expression induced by cisplatin. We also observed a remarkable influx of inflammatory cells and upregulation of cytokines in kidneys of cisplatin-treated MIOX-TG mice. Finally, analysis of genomic DNA in WT mice revealed cisplatin-induced hypomethylation of the MIOX promoter. These data suggest that MIOX overexpression exacerbates, whereas MIOX gene disruption protects against, cisplatin-induced AKI.
Inhibition of Aberrant MicroRNA-133a Expression in Endothelial Cells by Statin Prevents Endothelial Dysfunction by Targeting GTP Cyclohydrolase 1 in Vivo
Authors: Peng Li, Ya-Ling Yin, Tao Guo, Xue-Ying Sun, Hui Ma, Mo-Li Zhu, Fan-Rong Zhao, Ping Xu, Yuan Chen, Guang-Rui Wan, Fan Jiang, Qi-Sheng Peng, Chao Liu, Li-Ying Liu, Shuang-Xi Wang
Journal: Circulation (2016)

GTP cyclohydrolase 1 (GCH1) deficiency is critical for endothelial nitric oxide synthase uncoupling in endothelial dysfunction. MicroRNAs (miRs) are a class of regulatory RNAs that negatively regulate gene expression. We investigated whether statins prevent endothelial dysfunction via miR-dependent GCH1 upregulation.Endothelial function was assessed by measuring acetylcholine-induced vasorelaxation in the organ chamber. MiR-133a expression was assessed by quantitative reverse transcription polymerase chain reaction and fluorescence in situ hybridization.We first demonstrated that GCH1 mRNA is a target of miR-133a. In endothelial cells, miR-133a was robustly induced by cytokines/oxidants and inhibited by lovastatin. Furthermore, lovastatin upregulated GCH1 and tetrahydrobiopterin, and recoupled endothelial nitric oxide synthase in stressed endothelial cells. These actions of lovastatin were abolished by enforced miR-133a expression and were mirrored by a miR-133a antagomir. In mice, hyperlipidemia- or hyperglycemia-induced ectopic miR-133a expression in the vascular endothelium, reduced GCH1 protein and tetrahydrobiopterin levels, and impaired endothelial function, which were reversed by lovastatin or miR-133a antagomir. These beneficial effects of lovastatin in mice were abrogated by in vivo miR-133a overexpression or GCH1 knockdown. In rats, multiple cardiovascular risk factors including hyperglycemia, dyslipidemia, and hyperhomocysteinemia resulted in increased miR-133a vascular expression, reduced GCH1 expression, uncoupled endothelial nitric oxide synthase function, and induced endothelial dysfunction, which were prevented by lovastatin.Statin inhibits aberrant miR-133a expression in the vascular endothelium to prevent endothelial dysfunction by targeting GCH1. Therefore, miR-133a represents an important therapeutic target for preventing cardiovascular diseases.
Registry of Monoclonal Gammopathies (RMG) in the Czech Republic
Authors: Jakub Radocha, Ludek Pour, Ivan Spicka, Vlastimil Scudla, Evzen Gregora, Hana Frankova, Roman Hajek, Miroslava Schutzova, Michal Sykora, Petr Kessler, Dagmar Adamova, Marek Wrobel, Lenka Sedlarikova, Sabina Sevcikova, Daniel Horinek, Jana Pelcova, Lucie Brozova, Jiri Jarkovsky, Vladimir Maisnar
Journal: Blood (2015)
Functional Characterization of a Recombinant FVIIa Drug Candidate
Authors: Peter L Turecek, Katalin Varadi, Susanne Vejda, Ernst Boehm, Hanspeter Rottensteiner, Hans Peter Schwarz, Artur Mitterer, Wolfgang Mundt, Hartmut J. Ehrlich, Friedrich Scheiflinger
Journal: Blood (2010)
Allogeneic but Not Autologous Stem Cell Transplant Attenuates the Negative Prognostic Impact Dictated By Pretransplant MRD Positivity
Authors: Francesco Buccisano, Luca Maurillo, Maria Ilaria Del Principe, Gottardo De Angelis, Raffaella Cerretti, Concetta Ditto, Ambra Di Veroli, Alessandra Picardi, Laura Cudillo, Mariagiovanna Cefalo, Chiara Sarlo, Giorgia Fedele, Marco Refrigeri, Francesco Lo Coco, William Arcese, Sergio Amadori, Adriano Venditti
Journal: Blood (2014)
CALM-AF10 Positive Acute Myeloid Leukemias: A French Cohort of 18 Patients.
Authors: Cecile Borel, Nicole Dastugue, Thomas Prebet, Norbert Vey, Marie-Joelle Mozziconacci, Christian Bastard, Christine Lefebvre, Francine Mugneret, Dominique Leroux, Faezeh Legrand, Marie Agnes Collonges Rame, Sorin Visanica, Jean Philippe Rault, Nathalie Gachard, Arnaud Pigneux, Eric Lippert, Sylvie Taviaux, Pascaline Talmant, Murielle Roussel, Françoise Huguet, Eric Delabesse, Christian Recher
Journal: Blood (2008)
Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 Trial
Authors: Takashi Watanabe, Yasuo Morishima, Taro Shibata, Nobuo Maseki, Tomohiro Kinoshita, Takayo Suzuki, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Masafumi Taniwaki, Naokuni Uike, Kengo Takeuchi, Shigeru Nawano, Takashi Terauchi, Kunihiro Tsukasaki, Tomomitsu Hotta, Kensei Tobinai
Journal: Blood (2010)
Changes in Bone Metabolism Induced by Short-Term Treatment with G-CSF for the Mobilization of Allogeneic Hematopoietic Progenitor Cells.
Authors: Frank P. Kroschinsky, Sybille Bergmann, Kirsten Poppe-Thiede, Gabriele Siegert, Claudia Rutt, Gerhard Ehninger
Journal: Blood (2005)
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
Authors: Noel G McElvaney, Jonathan Burdon, Mark Holmes, Allan Glanville, Peter A B Wark, Philip J Thompson, Paul Hernandez, Jan Chlumsky, Helmut Teschler, Joachim H Ficker, Niels Seersholm, Alan Altraja, Riitta Mäkitaro, Joanna Chorostowska-Wynimko, Marek Sanak, Paul I Stoicescu, Eeva Piitulainen, Oliver Vit, Marion Wencker, Michael A Tortorici, Michael Fries, Jonathan M Edelman, Kenneth R Chapman
Journal: The Lancet Respiratory Medicine (2016)